(Bloomberg) -- The news on Avandia shaved $13.7
billion from GlaxoSmithKline Plc's market value this week.
Doctors scurried to answer patient queries about the safety of
their diabetes drug. U.S. lawmakers demanded an investigation.
Chalk it all up to Steven Nissen. A study by Nissen, one of
the top U.S. heart researchers, revealed that Glaxo's popular
diabetes drug may raise heart attack risks. While the last word
on the product's safety isn't in, Nissen's pivotal role in
uncovering and publicizing the side effects of this and several
other drugs, including Merck & Co.'s Vioxx, is clear.
Read more at Bloomberg Exclusive News
billion from GlaxoSmithKline Plc's market value this week.
Doctors scurried to answer patient queries about the safety of
their diabetes drug. U.S. lawmakers demanded an investigation.
Chalk it all up to Steven Nissen. A study by Nissen, one of
the top U.S. heart researchers, revealed that Glaxo's popular
diabetes drug may raise heart attack risks. While the last word
on the product's safety isn't in, Nissen's pivotal role in
uncovering and publicizing the side effects of this and several
other drugs, including Merck & Co.'s Vioxx, is clear.
Read more at Bloomberg Exclusive News
No comments:
Post a Comment